Besides its association with metabolic diseases, the GIP-GIPR axis is also gaining interest because of its inappropriate expression and activation in some human endocrine tumors, as the GIP-GIPR axis may be involved in tumor development and therefore, offers a potential target for a new therapeutic approach [101]. This evidence concerns the gene GIPR and metabolic disease.